Huntington's Disease
Huntington's Disease is a neurological condition associated with movement symptoms such as chorea and changes in functional ability. The research discussed here examines whether options including Acetyl-L-Carnitine (ALCAR), CBD (Cannabidiol), and Creatine may affect symptoms or functional decline, but these findings do not establish them as effective treatments.
A focused look at Huntington's Disease within neurological health.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
What studies found for each option, best evidence first.
2 options:1 some evidence1 not enough evidence
DancepracticeSome evidence it helpsSize of effect: Not known
Some human studies found a benefit. More research could change this.
All 2 studies with a clear result found a benefit.
A review describes dance as effective in Huntington’s Disease rehabilitation. A separate review reports that contemporary dance reduced motor impairment and improved executive function, alongside increases in grey matter volume in areas involved in somatosensory and spatial body processing.
Open the Dance pageAcceptance and Commitment Therapy (ACT)practiceNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A case report described one person with Huntington's Disease whose depressive symptoms decreased from PHQ-9: 11 to 6 after a 6-session ACT intervention, with improvements across three HDQoL domains. A single case cannot establish how often these changes occur.
Open the Acceptance and Commitment Therapy (ACT) page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition2 listedMost likely to help, from the evidence we have
- →PracticesDanceCertaintyMediumSourceRCT
A review describes dance as effective in Huntington’s Disease rehabilitation. A separate review reports that contemporary dance reduced motor impairment and improved executive function, alongside increases in grey matter volume in areas involved in somatosensory and spatial body processing.
Who was studied
- People with a condition
- Huntingtons Disease
- Multiple Sclerosis
- Parkinsons Disease
- Stroke
Open DanceStudy result
Systematic review described in abstract as finding effectiveness in Huntington's disease rehabilitation, without outcome or effect size detail.
Low probability(1)
- →PracticesAcceptance and Commitment Therapy (ACT)CertaintyLowSourceClinical
A case report described one person with Huntington's Disease whose depressive symptoms decreased from PHQ-9: 11 to 6 after a 6-session ACT intervention, with improvements across three HDQoL domains. A single case cannot establish how often these changes occur.
Who was studied
- People with a condition
Open Acceptance and Commitment Therapy (ACT)Study result
Single case report showing clinically significant reduction in depressive symptoms (PHQ-9: 11 to 6, exceeding MCID) and improved quality of life across three HDQoL domains following a 6-session ACT intervention; narrative review of ACT effectiveness in other neurodegenerative disorders supports prom
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Huntington's Disease worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Huntington's Disease is a neurological condition associated with movement symptoms such as chorea and changes in functional ability. The research discussed here examines whether options including Acetyl-L-Carnitine (ALCAR), CBD (Cannabidiol), and Creatine may affect symptoms or functional decline, but these findings do not establish them as effective treatments.
Evidence-backed options
The options associated with Huntington's disease have not established a clear, reliable benefit. Acetyl-L-Carnitine (ALCAR) was neither efficient nor toxic in the reviewed assessment, although some patients felt better. This may represent a subtle improvement that the assessment methods could not detect, rather than a demonstrated effect on the condition.
CBD (Cannabidiol) did not improve chorea or other symptoms when given orally at a dose of 10 mg/kg. Creatine findings do not support its use for delaying functional decline in early manifest Huntington's disease. These findings address different outcomes and do not show that any of these options changes the underlying course of the condition.
The available summaries do not establish how quickly effects appeared, how long treatment was continued, or whether benefits differed across stages or symptom patterns. Overall, the evidence is thin, and the findings do not provide a consistent basis for assuming benefit. Anyone considering an option for Huntington's disease should discuss the evidence and its relevance to their situation with a clinician.